Company news
Unicycive Therapeutics, Inc. news in 2026
Unicycive Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
November 16, 2026
Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
November 4, 2026
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027
October 21, 2026
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
October 1, 2026
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
September 29, 2026
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 1, 2026
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
March 29, 2026
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
February 4, 2026
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
January 29, 2026
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
January 29, 2026
Decks in 2026
- Investor Presentation (November 2026)
Investor deck · 33 slides · November 2026
- Investor Presentation (October 2026)
Investor deck · 33 slides · October 2026